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Treating SDB may improve cardiac function in patients with CHF. CPAP reportedly suppresses the abnormal breathing pattern, attenuates sympathetic nervous activity, 11 and improves the left ventricular ejection fraction (LVEF) in CHF patients with either OSA or CSR-CSA. 12 Furthermore, there are several reports about mid-term (several months) effects of ASV on cardiac function, 8,13-16 and we have reported that ASV improves the long-term prognosis in patients with CHF and CSR-CSA. 17 However, the short-term (a single night) effects, and the mechanisms of O2 and ASV on cardiac function in patients with CHF and CSR-CSA, are not fully understood.
Sympathetic nervous activation, ongoing myocardial damage, and inflammation play critical roles in the progression of CHF and are associated with adverse prognosis. Levels of plasma noradrenalin, 18 serum troponin T, 19,20 and C-reactive protein (CRP) 21, 22 are useful prognostic markers in patients with CHF. However, the acute effects of O2 and ASV on atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), plasma noradrenalin, serum troponin T, and CRP levels have not been rigorously examined.
ASV is more useful for improving CSR-CSA than O2, as previously reported, 9 but compliance with long-term use of ASV is not enough. On the other hand, O2 therapy has better compliance than ASV. Therefore, the primary purpose of the present study was to review the short-term (a single night) multiple effects in suppressing SDB (CSR-CSA dominant) and neurohumoral abnormalities of ASV compared with O2. The secondary purpose was to determine which of ASV or O2 was more effective for CHF with SDB in a single night. We compared the short-term (a single night) multiple effects of ASV and O2 on cardiac function, sympathetic nervous activity, ongoing myocardial damage, and inflammation in CHF patients with SDB (CSR-CSA dominant).
Methods

Study Subjects and Study Protocol
This study enrolled 42 consecutive patients with CHF and SDB (CSR-CSA dominant) who were referred for overnight polysomnography (PSG) at Fukushima Medical University. The inclusion criteria were (1) the presence of symptomatic CHF, which was defined as the New York Heart Association (NYHA) class ≥II, (2) LVEF <50%, (3) enforcement of standard pharmacotherapy (including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers and diuretics), (4) stable clinical status, which was defined as receiving optimal medical therapy and without worsening of CHF at least 3 months prior to study enrollment, and (5) diagnosed as having moderate-severe SDB, and CSR-CSA dominant, which was defined as an apnea hypopnea index (AHI) ≥15/h with a majority of central sleep apnea events. The exclusion criteria were (1) age <20 or >80 years, (2) resynchronization therapy within 6 months prior to study enrollment, (3) the presence of severe chronic pulmonary disease, (4) on dialysis, (5) a history of stroke with neurological deficit, (6) psychotic disorders, (7) pharyngeal disease, and (8) acute coronary syndrome and acute decompensated heart failure.
This study used an acute prospective random crossover design. We examined 3 consecutive days because of the exclusion of a change in HF condition and treatment. We performed polysomnography for 3 sequential night (baseline, O2, and ASV): baseline PSG done on the first night, and then subjects were tested on 2 treatment nights in random order: O2 and ASV. The 42 patients were divided into 2 groups and randomly assigned to either baseline, O2, and ASV (n=21) or baseline, ASV, and O2 (n=21). In addition, we measured levels of ANP, BNP, plasma noradrenalin, high-sensitivity troponin T, highsensitivity C-reactive protein (hsCRP) each morning, and 24-h accumulated urinary catecholamines. Written informed consent was given by all study subjects. The study protocol was approved by the Ethical Committee of Fukushima Medical University. 
Polysomnography
Echocardiography
Echocardiography was performed blindly only at baseline daytime using the standard techniques by an experienced echocardiographer. Two-dimensional echocardiographic images were acquired from the parasternal long and short axes, apical long axis, and apical 4-chamber views. Echocardiographic parameters investigated were left ventricular end-diastolic volume index (LVEDVI), left ventricular end-systolic volume index (LVESVI), LVEF, left atrial volume index (LAVI), estimated right ventricular systolic pressure (RVPS), and the ratio of early transmitral flow velocity to mitral annular velocity (E/E'). The LVEDVI, LVESVI, LVEF and LAVI were calculated using a modification of Simpson's method. E/E' was calculated by transmitral Doppler flow and tissue Doppler imaging. All recordings were performed on the ultrasound system (ACUSON Sequoia, Siemens Medical Solutions USA, Inc, Mountain View, CA, USA).
Measurement of ANP, BNP, Plasma Noradrenalin, High-Sensitivity Troponin T, hsCRP, and Urinary Catecholamines
The patients underwent polysomnography for 3 consecutive Overnight Effects of ASV for CHF With SDB days. After waking up each morning, we asked the patients to rest for at least 30 min before we took blood samples to measure levels of plasma ANP, plasma BNP, plasma noradrenalin, serum high-sensitive troponin T, and serum hsCRP. The 24-h urinary catecholamines, such as metanephrine and normetanephrine, were measured.
Oxygen Therapy
Patients were administered oxygen at a rate of 3 L/min through a nasal cannula during sleep as previously described. 6,7
Adaptive Servo-Ventilation (ASV) We used ASV (VPAP Adapt SV/Auto Set CS, ResMed, Sydney, NSW, Australia). Patients underwent a titration of the device overnight while attended by the polysomnographer. The aim was to reduce the AHI to <10/h using a minimum of positive airway pressure. In summary, we set expiratory positive airway pressure (EEP) to cause the disappearance of OSA, and next set minimum and maximum pressure support (PS) to cause the disappearance CSR-CSA. All patients were able to tolerate ASV until the next morning.
Statistical Analysis
Data are presented as mean ± SD. ANP and BNP are presented as median and interquartile range. The data measured repeatedly at baseline, on O2, and on ASV, such as the polysomnographic data and blood examinations, were analyzed by 1-way repeated-measures analysis of variance (ANOVA) followed by Bonferroni post-hoc test. ANP and BNP were analyzed by Kruskal-Wallis test. P<0.05 was considered significant for all comparisons. All analyses were performed using a statistical software package (StatView version 5.0, SAS Institute, Abacus Concepts, Berkeley, CA, USA).
Results
Clinical Characteristics of Study Subjects
Clinical characteristics are shown in Table 1 . Males accounted for 88%, and the major etiology of CHF was cardiomyopathy (69%); 7 patients underwent cardiac resynchronization therapy. Median BNP was 245.8 pg/ml, and mean LVEF was 34.6%. The results of the polysomnographic recordings (baseline) are shown in Table 2 . Mean AHI was 39.0/h, mean CAI was 17.6/h, OAI was 2.6/h and mean lowest SPO2 was 79.1%. These data suggest that these patients had severe SDB (CSR-CSA dominant).
Effects of O2 and ASV on Polysomnographic Data and Vital Signs
We set the EEP to eliminate OSA, and then set the minimum and maximum PS to eliminate CSR-CSA by attended manual titration. Consequently, mean EEP was 6.0±2.0 cmH2O (range 4-10), mean minimum PS was 3.6±2.4 cmH2O (range 3-6), mean maximum PS was 8.5±4.1 cmH2O (range 6-12) and the respiratory rate was set to automatic in the present study. All patients were successfully titrated on ASV. Table 2 shows the polysomnographic data of the patients at baseline, on O2, and on ASV. Both O2 and ASV significantly improved the polysomnographic data in terms of AHI, CAI, HI, arousal index, 3%ODI, lowest SPO2, mean SPO2, CT90, and CT95 (P<0.01 for each) compared to baseline. However, only ASV increased the SWS (P<0.05). In addition, AHI and OAI were significantly lower with ASV than with O2 (P<0.05). The mean SPO2 was significantly higher with O2 than with ASV (P<0.05). By the next morning, both O2 and ASV had reduced the mean heart rate during sleep (P<0.01), the heart rate during REM (P<0.01) and NREM sleep (P<0.01), and systolic and diastolic blood pressures ( Table 2) .
Effects of O2 and ASV on Neuropeptides, Plasma Noradrenalin, High-Sensitivity Troponin T, hsCRP, and Urinary Catecholamines ASV reduced the levels of ANP (P<0.01), BNP (P<0.01), plas- E/E' 13.4±6.1 † Data are presented as median (inter quartile range). CHF, chronic heart failure; BMI, body mass index; NYHA, New York Heart Association; ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; LVEDVI, left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index; LVEF, left ventricular ejection fraction; LAVI, left atrial volume index; RVPS, right ventricular systolic pressure; E/E', ratio of early transmitral flow velocity to mitral annular velocity. YOSHIHISA A et al. ma noradrenalin (P<0.01), urinary catecholamine excretion (P<0.01), and high-sensitive troponin T (P<0.05) compared to baseline ( Table 2) . O2 reduced plasma noradrenalin (P<0.05), urinary catecholamines (P<0.01), and high-sensitivity troponin T (P<0.05), but not ANP and BNP. However, the hsCRP level did not change with either O2 or ASV.
Discussion
Effects of O2 and ASV on Cardiac Overload in HF
Noninvasive ventilation increases cardiac output in HF patients whose pulmonary arterial wedge pressure is high. 26, 27 Intrathoracic positive pressure by noninvasive ventilation is thought to reduce cardiac preload and afterload, 28 and decrease left ventricular volume, leading to an improvement in mitral regurgitation, 16,27 but it is still uncertain whether short-term use of ASV is beneficial for cardiac overload in CHF patients with SDB. There are several reports about a reduction in the BNP level after several months of using ASV. 17,25,29, 30 In the present study, only 'single night' use of ASV directly decreased cardiac overload as demonstrated by significant decreases in the ANP and BNP levels in CHF patients with SDB. This effect by ASV seems to be driven by intrathoracic positive pressure. O2 does not have a direct effect of decreasing cardiac end-diastolic wall stress. To the best of our knowledge, this is the first reporting of acute reduction of cardiac overload in patients with CHF and SDB (CSR-CSA dominant) by the use of ASV in a single night.
Effects of O2 and ASV on Sympathetic Nervous Activity in HF
Sympathetic nervous activation plays a critical role in the progression of CHF and is associated with adverse clinical outcomes. 18 Sympathetic nervous activity affects the mean heart rate during sleep, arousal index, plasma noradrenalin level, and daily urinary catecholamine excretion, which were reduced by O2 and ASV in the present study. The magnitude of the heart rate reduction and sympathetic nervous activity are associated with a survival benefit in HF patients under β-blocker therapy. 31, 32 In addition, only ASV increased SWS in the present study. High-quality sleep decreases sympathetic nervous activity. ASV and O2 decreased both the plasma noradrenalin level the next morning and daily urinary catecholamine excretion. It has been reported that mid-term (several months) use of O2 and CPAP attenuates cardiac sympathetic nervous activity in patients with CHF and CSR-CSA. 7,33 Short-term use of ASV improves periodic breathing and attenuates sympathetic overactivation, such as muscle sympathetic nerve activity. 34 
Effects of O2 and ASV on Myocardial Damage and Inflammation in HF
High-sensitivity troponin T as a marker of ongoing myocardial damage 19,20 and hsCRP as a marker of inflammation 21, 22 are useful in understanding the clinical condition of CHF pa- tients. In the present study, O2 and ASV reduced high-sensitive troponin T levels, but this effect may depend on an improvement in oxygenation, and a decrease in sympathetic activity and cardiac overload. Although, mid-term (4 weeks) use of ASV has an anti-inflammatory effect, 25 we did not observe such an effect with single-night use of O2 and ASV. Further examination may be required to confirm the anti-inflammatory effect of O2 and/or ASV.
O2 and ASV for HF With CSR-CSA O2 improves exercise capacity and attenuates cardiac sympathetic nervous activity in patients with CHF and CSR-CSA. 6,7 A large-scale randomized clinical trial, the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure (CANPAP), has shown that CPAP does not improve long-term transplant-free survival in CHF patients with CSR-CSA. 35 However, in a CANPAP subanalysis, improvement of CSR-CSA (especially AHI <15) was important for cardiac function and prognosis in CHF patients. 36 ASV has an automatic airway tracing feedback function and several advantages (eg, suppressing AHI in CSR-CSA) over CPAP, bi-level PAP, and O2 have been reported. 9,10,13 ASV has better compliance 13 and improvement effect on CSR-CSA than CPAP, so the use of ASV may have resulted in good consequences for cardiac function and prognosis. 8,10,17,25, 37 In the present study, the indices of improved SDB (eg, AHI, OAI, SWS) by O2 were inferior to those for ASV, but O2 has good compliance, and we can expect long-term use of O2. Both ASV and O2 are important non-pharmacotherapies for HF patients with CSR-CSA.
Study Limitations
Firstly, a crossover design with 2 active treatment arms does not allow for comparison with true placebo and therefore does not account for time-dependent effects. The subjects did not have washout periods before undergoing ASV or O2. The crossover design has limitations compared to an independent parallel group design. Secondly, polysomnography was done on consecutive days. We are unclear whether the interval between the tests was sufficient for the patient to return to the baseline condition. Thirdly, we used only a fixed O2 flow of 3 L/min, as previously described, 7,8 and we did not examine the effects of another dose of O2. Finally, acute effects do not necessarily predict long-term effects. However, an acute study has the merit of excluding effects in the long term by a change in the HF condition and treatment. Further, long-term studies are necessary to establish ASV as a promising therapy for CHF patients with SDB.
Conclusions
In this study, use of ASV led to more improvement in SDB (CSR-CSA dominant) than did O2 therapy. To the best of our knowledge, the present study is the first to show an acute shortterm (a single night) beneficial effect of ASV on multiple parameters such as ANP, BNP, noradrenalin, high-sensitive troponin T, and urinary catecholamine levels. These data suggest that short-term use of ASV has the multiple effect of not only improving SDB (CSR-CSA dominant) but also attenuating sympathetic nervous activity, reducing cardiac overload and myocardial damage. ASV might be a promising non-pharmacotherapy for CHF. On the other hand, although O2 was inferior to ASV in terms of improving SDB, it has good compliance. For patients who cannot use ASV, O2 to some extent is effective for CSR-CSA and suppressing sympathetic nervous activation and myocardial damage.
